Our website does not fully support your browser.

We've detected that you are using an older version of Internet Explorer. Your commerce experience may be limited. Please update your browser to Internet Explorer 11 or above.

Product Availability Update

Promega Manufacturing and Delivery Systems continue to be fully operational during the COVID-19 outbreak. Our teams are in regular contact with suppliers and distributors worldwide and are taking all steps necessary to address both demands for diagnostic tools and reliable delivery of all products as quickly as possible. Learn more

We believe this site might serve you best:

United States

United States

Language: English

Promega's Cookie Policy

Our website uses functional cookies that do not collect any personal information or track your browsing activity. When you select your country, you agree that we can place these functional cookies on your device.

Post-Translational Modification Enzymes: How to Interrogate Key Drug Targets

  • Demonstrating how cellular mechanisms driven by PTM can be addressed by analyzing the biochemical activities of the involved enzymes using a simple suite of bioluminescent nucleotide detection assays


Post-translational modifications (PTMs) amplify diverse cellular functions by covalently adding functional groups such as phosphate, acetate, amide, or methyl groups to proteins. The PTM enzymes and resulting modifications are too numerous to list here. Phosphorylation, a common mechanism in regulating downstream cellular signaling (i.e., via kinases), is one of the most common PTMs. Many eukaryotic proteins can also be modified by glycosylation. Attaching carbohydrates to proteins is implicated in protein folding, improved stability and other regulatory functions such as signaling. Environmental or pathological conditions can lead to dysregulation of PTM activities resulting in the perturbation of the intracellular networks governed by each. As a result, PTM enzymes such as kinases and glycosyltransferases are targets or are starting to be targeted for drug development. 

Traditional assay technologies such as mass spectrometry, or antibody-based techniques such as ELISA or western blotting are cumbersome and not easily amenable to high throughput drug discovery. We have developed a detection technology platform highly suitable to screening of PTM enzymatic activities when nucleotides are substrates or products. In this webinar we will demonstrate how cellular mechanisms driven by PTM can be addressed by analyzing the biochemical activities of the involved enzymes using a simple suite of bioluminescent nucleotide detection assays.



Hicham Zegzouti, PhD
Senior Research Scientist

Dr. Hicham Zegzouti is a Senior Research Scientist in Promega Assay Design-R&D. His group develops Assay technologies to interrogate diverse enzyme activities and cellular pathways (kinases, glycosyltransferases, and other drug targets). Dr. Zegzouti received his PhD in 1997 from the National Polytechnic Institute of Toulouse, France. Prior to joining Promega, he was a postdoctoral researcher in Molecular, Cell and Developmental Biology at UC-Los Angeles studying auxin hormone signaling in an Arabidopsis plant model. His work focused on the identification and characterization of AGC kinase family and its regulation during plant development. Dr. Zegzouti has authored 14 journal articles and book chapters, co-edited a methods book and is an inventor for one issued and 4 pending patents.

We love to talk science.

Sign up to receive monthly invitations to our webinars.

Sign Up